Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to evaluate the feasibility and the effect of daily, individual, supervised and structured exercise training before radiotherapy in patients diagnosed with Non-Small Cell Lung Cancer. Primary outcome is maximal oxygen uptake (VO2peak). The hypotheses are that patients who undergo daily exercise training will increase VO2peak, functional capacity (measured by 6-minute walk test (6MWD)) and lung function (forced expired volume in one second (FEV1)).


Clinical Trial Description

Pre intervention screening: Each patient was screened by a clinical nurse specialist prior to participating in the study. Before baseline and post test the patient was screened by a research physiotherapist and/or human physiology students. If one of the following criteria were met, the patient was prohibited from being tested on that day: diastolic blood pressure <45 or >95, heart rate (HR) at rest >115/min, temperature > 38 0C, respiratory rate at rest >30/min, infection requiring treatment, fresh bleeding, total leucocyte count <1.0 109/L or platelets <50 109/L. Control - Usual care: The patients randomized to the control group received no training but conducted baseline and post test (6MWD, spirometry, VO2peak and questionnaires) just as the intervention group. Furthermore, patients in control were equipped with a Garmin vivo-smart HR® activity tracker every day in 24h during the course of radiotherapy treatment. Intervention - The patients randomized to the intervention group received daily training and conducted baseline and post test (6MWD, spirometry, VO2peak and questionnaires). Furthermore, patients were equipped with a Garmin vivo-smart HR® activity tracker every day in 24h during the course of radiotherapy treatment. The supervised daily training was carried out individually and each session had a duration of 20 minutes before patients individual prescribed radiotherapy. Training was conducted at National Hospital of Denmark: Department of Radiation Oncology , section 3981, entry 39. supervised by a research physiotherapist and/or human physiology students. Statistical analysis sample size: According to the sample size the calculation is performed on the basis of alteration in VO2peak from the study "EXHALE" (55 patients who completed a 6 weeks training period). The calculation is based on an increase of 200 ml/min in VO2peak for patients in the intervention group (SD = 2,48) and it is assumed that the patients in the control group will have a reduction of 100 ml/min (SD = 2,48). Assumptions for calculation of patient numbers are as follows: Type 1 error 0.05, type 2 error 0.20, SD 2.48. This leads to a total number of 24 patients (12 in each arm). A drop-out rate of 40% is included. Therefore another 16 patients is added, which gives a sample size of 40 patients (20 in each arm). Data entry is carried out in the Open Clinica and data analyses will be performed using the computer programs R-Studio/R and SPSS. Data from questionnaires will be analyzed by SPSS. All other data will be analyzed by R. Differences between groups will be analyzed by an unparried t-test whereas differences within groups will be analyzed by a parried t-test. All categorical data are analyzed using the Pearson χ2 tests. Other data (e.g., from questionnaires) are analyzed using logistic regression and chi square or Mantel Haenzel test. Significance level is set at 0.05. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03066271
Study type Interventional
Source Rigshospitalet, Denmark
Contact
Status Active, not recruiting
Phase N/A
Start date April 3, 2017
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Terminated NCT02677311 - GnRHA Therapy and Ovarian Preservation in Pediatric Cancer Patient N/A
Recruiting NCT03731130 - Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer
Completed NCT02979691 - Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01 Phase 2/Phase 3
Active, not recruiting NCT02969473 - Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT01381913 - Feasibility Trial of Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer N/A
Recruiting NCT03712774 - Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant or Definitive Chemoradiation in Patients With Esophageal Cancer
Terminated NCT03170115 - Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer Phase 2
Recruiting NCT02979795 - Translational Research in Identifying Molecular Mechanisms for Rectal Cancer Metastasis N/A
Recruiting NCT05394415 - Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC Phase 1/Phase 2
Recruiting NCT03427684 - Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer Phase 1/Phase 2
Completed NCT03923309 - Oncologic Risk of Rectal Preservation Against Medical Advice After Chemoradiotherapy for Rectal Cancer
Active, not recruiting NCT03475186 - Testing Ramipril to Prevent Memory Loss in People With Glioblastoma Phase 2
Recruiting NCT03623737 - Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC Phase 2/Phase 3
Completed NCT02813967 - S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer Phase 3
Completed NCT02966769 - N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation N/A
Completed NCT03298204 - Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01
Completed NCT03461341 - European iNvestigation of SUrveillance After Resection for Esophageal Cancer
Completed NCT03021668 - Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections N/A
Recruiting NCT02938195 - Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal Cancer Phase 2
Recruiting NCT03225300 - Simultaneous Integrated Boost in Malignant Glioma Patients Treated With Chemoradiation N/A